CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the...
- Mechanism
- Curator reviewed
CAD106 is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. CAD106 consists of two components, the Immunodrug carrier Qb coupled with a fragment of the beta-amyloid-protein. In animal studies it has been shown that treatment with CAD106 can block the formation of beta-amyloid plaques in the brain.
- Primary indication
- Investigated for use/treatment in alzheimer's disease.Curator reviewed
- Code names
- CAD106
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Amilomotide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account